10月23日，再鼎医药有限公司（以下简称“再鼎医药”）公布了旗下在研抗体偶联药物（ADC）Zocilurtatug Pelitecan（以下简称“Zoci”，原代号ZL-1310）用于一线广泛期小细胞肺癌的全球Ⅰb期临床研究数据。相关结果将于10月26日在2026年欧洲肿瘤内科学会（ESMO）大会上展示。 数据显示，在推荐的Ⅲ期研究剂量1.6mg/kg下，Zoci联合阿替利珠单抗治疗33例患者，...
Source Link10月23日，再鼎医药有限公司（以下简称“再鼎医药”）公布了旗下在研抗体偶联药物（ADC）Zocilurtatug Pelitecan（以下简称“Zoci”，原代号ZL-1310）用于一线广泛期小细胞肺癌的全球Ⅰb期临床研究数据。相关结果将于10月26日在2026年欧洲肿瘤内科学会（ESMO）大会上展示。 数据显示，在推荐的Ⅲ期研究剂量1.6mg/kg下，Zoci联合阿替利珠单抗治疗33例患者，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.